{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:21:18Z","timestamp":1740122478428,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["Multi-center Clinical Research Project of Peking University First Hospital","No. 2022CR67"],"award-info":[{"award-number":["Multi-center Clinical Research Project of Peking University First Hospital","No. 2022CR67"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073935","81973395"],"award-info":[{"award-number":["82073935","81973395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to identify the optimal anti-platelet therapy in older acute coronary syndrome (ACS) patients with a mean age\u2009\u2265\u200960 years by comparing the efficacy and safety of different anti-platelet therapies. The selection of antiplatelet therapy in older patients with ACS is a clinical challenge. Numerous evidences indicate that the de-escalation of dual anti-platelet therapy (DAPT) or P2Y12 inhibitor monotherapy may reduce bleeding risk without increasing thrombotic events. However, there is a lack of systematic reviews and optimal strategy analysis regarding older ACS patients. Randomized controlled trials (RCTs) of anti-platelet therapy in older ACS patients were identified. Major adverse cardiovascular events (MACE) were the primary outcome. Secondary outcomes included all death, cardiovascular death, myocardial infarction, stroke, stent thrombosis, and trial-defined major bleeding. Frequentist and Bayesian network meta-analyses were conducted. Treatments were ranked on posterior probability. Summary odds ratios (ORs) were estimated using Bayesian network meta-analysis. A total of 12 RCTs including 59,284 older ACS patients treated with five anti-platelet strategies were included. Ticagrelor monotherapy after 3 months DAPT was comparable to the other strategies (OR 0.73; 95% CI 0.32\u20131.6) in terms of MACE risk. Additionally, P score analysis and SUCRA Bayesian analysis showed that it was the most beneficial treatment for all deaths, cardiovascular death and revascularization. For safety, although there was no significant difference in direct comparisons, both SUCRA Bayesian (0.806) and P score (0.519) analysis suggested that ticagrelor monotherapy was the safest strategy. The current evidence demonstrated that ticagrelor monotherapy after 3 months DAPT may be a promising approach for achieving a more favorable balance between risk and benefit for older ACS patients, with a relatively low bleeding risk and without an increased risk of MACE events. Moreover, it remains the preferred option for clinical outcomes such as all death, CV death and revascularization. Further high-quality and long-term studies are required to validate anti-platelet therapies among older ACS patients.<\/jats:p>","DOI":"10.1007\/s11239-023-02875-x","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T14:01:56Z","timestamp":1691416916000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients"],"prefix":"10.1007","volume":"57","author":[{"given":"Shuang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"issue":"10","key":"2875_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68(10):1082\u20131115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2875_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cvr\/cvt115","volume":"99","author":"C Chaabane","year":"2013","unstructured":"Chaabane C, Otsuka F, Virmani R et al (2013) Biological responses in stented arteries. Cardiovasc Res 99(2):353\u2013363. https:\/\/doi.org\/10.1093\/cvr\/cvt115","journal-title":"Cardiovasc Res"},{"issue":"Suppl B","key":"2875_CR3","doi-asserted-by":"publisher","first-page":"B3","DOI":"10.1093\/eurheartjsupp\/suac001","volume":"24","author":"P Tou\u0161ek","year":"2022","unstructured":"Tou\u0161ek P, Bauer D, Neuberg M et al (2022) Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe. Eur Heart J Suppl 24(Suppl B):B3-b9. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac001","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"2875_CR4","first-page":"304","volume":"151","author":"HM Krumholz","year":"1989","unstructured":"Krumholz HM (1989) The clinical challenges of myocardial infarction in the elderly. West J Med 151(3):304\u2013310","journal-title":"West J Med"},{"key":"2875_CR5","unstructured":"Husted S, James S Fau - Becker RC, Becker Rc Fau - Horrow J, et al Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. (1941\u20137705 (Electronic))"},{"issue":"11","key":"2875_CR6","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1111\/jgs.14833","volume":"65","author":"FT Bourgeois","year":"2017","unstructured":"Bourgeois FT, Orenstein L, Ballakur S et al (2017) Exclusion of elderly people from randomized clinical trials of drugs for ischemic heart disease. J Am Geriatr Soc 65(11):2354\u20132361. https:\/\/doi.org\/10.1111\/jgs.14833","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"2875_CR7","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1111\/jgs.14923","volume":"65","author":"JA Dodson","year":"2017","unstructured":"Dodson JA, Chaudhry SI, Krumholz HM (2017) Time for a new approach to studying older people with ischemic heart disease. J Am Geriatr Soc 65(11):2349\u20132351. https:\/\/doi.org\/10.1111\/jgs.14923","journal-title":"J Am Geriatr Soc"},{"key":"2875_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00725-6","author":"D Capodanno","year":"2022","unstructured":"Capodanno D, Baber U, Bhatt DL et al (2022) P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-022-00725-6","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2875_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39(3):213\u2013260. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"issue":"10233","key":"2875_CR10","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/s0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel M, Qaderdan K, Willemsen L et al (2020) Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 395(10233):1374\u20131381. https:\/\/doi.org\/10.1016\/s0140-6736(20)30325-1","journal-title":"Lancet"},{"issue":"10233","key":"2875_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel M, Qaderdan K, Willemsen L et al (2020) Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet (Lond, Engl) 395(10233):1374\u20131381. https:\/\/doi.org\/10.1016\/S0140-6736(20)30325-1","journal-title":"Lancet (Lond, Engl)"},{"issue":"18","key":"2875_CR12","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/circulationaha.120.050645","volume":"142","author":"K Szummer","year":"2020","unstructured":"Szummer K, Montez-Rath ME, Alfredsson J et al (2020) Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART Registry. Circulation 142(18):1700\u20131708. https:\/\/doi.org\/10.1161\/circulationaha.120.050645","journal-title":"Circulation"},{"issue":"11","key":"2875_CR13","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jgs.14576","volume":"64","author":"MW Rich","year":"2016","unstructured":"Rich MW, Chyun DA, Skolnick AH et al (2016) Knowledge gaps in cardiovascular care of older adults: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: executive summary. J Am Geriatr Soc 64(11):2185\u20132192. https:\/\/doi.org\/10.1111\/jgs.14576","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"2875_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","volume":"78","author":"S Shoji","year":"2021","unstructured":"Shoji S, Kuno T, Fujisaki T et al (2021) De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes. J Am Coll Cardiol 78(8):763\u2013777. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2875_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/ehjcvp\/pvaa101","volume":"8","author":"C Montalto","year":"2022","unstructured":"Montalto C, Morici N, Munaf\u00f2 AR et al (2022) Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 8(1):20\u201327. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa101","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2875_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ahj.2021.03.009","volume":"237","author":"T Fujisaki","year":"2021","unstructured":"Fujisaki T, Kuno T, Ando T et al (2021) Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: systematic review and meta-analysis. Am Heart J 237:34\u201344. https:\/\/doi.org\/10.1016\/j.ahj.2021.03.009","journal-title":"Am Heart J"},{"issue":"l4898","key":"2875_CR17","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366(l4898):2019. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"37","key":"2875_CR18","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","volume":"41","author":"U Baber","year":"2020","unstructured":"Baber U, Dangas G, Angiolillo DJ et al (2020) Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J 41(37):3533\u20133545. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa670","journal-title":"Eur Heart J"},{"issue":"10","key":"2875_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jacc.2019.12.067","volume":"75","author":"BM Scirica","year":"2020","unstructured":"Scirica BM, Bergmark BA, Morrow DA et al (2020) Nonculprit lesion myocardial infarction following percutaneous coronary intervention in patients with acute coronary syndrome. J Am Coll Cardiol 75(10):1095\u20131106. https:\/\/doi.org\/10.1016\/j.jacc.2019.12.067","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2875_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057. https:\/\/doi.org\/10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"2875_CR21","unstructured":"Marquis-Gravel G, Neely ML, Valgimigli M, et al Long-term bleeding risk prediction with dual antiplatelet therapy after acute coronary syndromes treated without revascularization. (1941\u20137705 (Electronic))"},{"key":"2875_CR22","unstructured":"Saito S, Isshiki T Fau-Kimura T, Kimura T Fau-Ogawa H, et al Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. (1347\u20134820 (Electronic))"},{"key":"2875_CR23","unstructured":"Wang H, Wang X Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome. (1176\u20136336 (Print))"},{"key":"2875_CR24","unstructured":"Motovska Z, Hlinomaz O, Miklik R, et al Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 Study. (1524\u20134539 (Electronic))"},{"key":"2875_CR25","unstructured":"Crimi G, Morici N, Ferrario M, et al Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. (2047\u20139980 (Electronic))"},{"issue":"16","key":"2875_CR26","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Sch\u00fcpke","year":"2019","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M et al (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381(16):1524\u20131534. https:\/\/doi.org\/10.1056\/NEJMoa1908973","journal-title":"N Engl J Med"},{"key":"2875_CR27","unstructured":"Gimbel M, Qaderdan K, Willemsen L, et al Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. (1474\u2013547X (Electronic))"},{"key":"2875_CR28","unstructured":"Kim BK, Hong SJ, Cho YH, et al Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO Randomized Clinical Trial. (1538\u20133598 (Electronic))"},{"issue":"23","key":"2875_CR29","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/circulationaha.119.041766","volume":"140","author":"DW Park","year":"2019","unstructured":"Park DW, Kwon O, Jang JS et al (2019) Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation 140(23):1865\u20131877. https:\/\/doi.org\/10.1161\/circulationaha.119.041766","journal-title":"Circulation"},{"key":"2875_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1389200224666230509104404","volume":"5","author":"X Wu","year":"2023","unstructured":"Wu X, Sia JEV, Hai M et al (2023) Physiologically based pharmacokinetic model for older adults and its application in geriatric drug research. Curr Drug Metab 5:25. https:\/\/doi.org\/10.2174\/1389200224666230509104404","journal-title":"Curr Drug Metab"},{"issue":"2","key":"2875_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cger.2012.01.007","volume":"28","author":"LC Sera","year":"2012","unstructured":"Sera LC, McPherson ML (2012) Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med 28(2):273\u2013286. https:\/\/doi.org\/10.1016\/j.cger.2012.01.007","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"2875_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/01.cir.0000048892.83521.58","volume":"107","author":"EG Lakatta","year":"2003","unstructured":"Lakatta EG, Levy D (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a \u201cset up\u201d for vascular disease. Circulation 107(1):139\u2013146. https:\/\/doi.org\/10.1161\/01.cir.0000048892.83521.58","journal-title":"Circulation"},{"issue":"44","key":"2875_CR33","doi-asserted-by":"publisher","first-page":"e27398","DOI":"10.1097\/md.0000000000027398","volume":"100","author":"S Alaamri","year":"2021","unstructured":"Alaamri S, Dalbhi SA (2021) Risk of bleeding with ticagrelor in elderly patients over 75 years old: a systematic review and meta-analysis. Medicine (Baltimore) 100(44):e27398. https:\/\/doi.org\/10.1097\/md.0000000000027398","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2875_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/circulationaha.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Ko\u0142odziejczak M et al (2020) Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation 142(2):150\u2013160. https:\/\/doi.org\/10.1161\/circulationaha.120.046786","journal-title":"Circulation"},{"issue":"2","key":"2875_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/ph16020232","volume":"16","author":"WH Feng","year":"2023","unstructured":"Feng WH, Chang YC, Lin YH et al (2023) P2Y12 Inhibitor monotherapy versus conventional dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: a meta-analysis. Pharmaceuticals (Basel) 16(2):232. https:\/\/doi.org\/10.3390\/ph16020232","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02875-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02875-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02875-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T13:09:26Z","timestamp":1706706566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02875-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02875-x","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"20 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}